131 Ⅰ加抗甲亢药物综合治疗甲亢的可行性研究

131 Ⅰ plus drug hyperthyroidism comprehensive feasibility study for the treatment of hyperthyroidism

目的探讨131Ⅰ加抗甲亢药物治疗甲亢的可行性。方法纳入我院2016年2月至2017年4月期间收治的81例甲亢患者,随机分为试验组和对照组,给予对照组患者抗甲亢药物治疗,给予试验组患者131Ⅰ加抗甲亢药物治疗。结果两组患者治疗前的甲状腺激素T3、FT3、T4、FT4水平比较存在的差异无统计学意义(P>0.05),治疗后试验组患者甲状腺激素T3、FT3、T4、FT4水平均较对照组患者低(P<0.05),不良反应发生率为7.31%,与对照组的5.00%比较无明显差异(P>0.05)。结论 131Ⅰ加抗甲亢药物治疗甲亢的临床疗效优于单一应用抗甲亢药物治疗,且不会增加患者的药物不良反应发生率,具有应用可行性。

objective to investigate 131Ⅰplus resistance to the feasibility of the hyperthyroidism drug treatment of hyperthyroidism.Methods in our hospital in February 2016 to April 2016 admitted during the period of 81 hyperthyroidism patients,randomly divided into experimental group and the control group,control group patients were given,and the hyperthyroidism drug therapy,Ⅰplus 131 experimental group patients were given,and the hyperthyroidism drug therapy.Results the two groups before treatment in patients with thyroid hormone T3,FT3,T4,FT4 level is no statistically significant differences(P>0.05),treatment group after treatment in patients with shaped gland hormone T3,FT3,T4,FT4 levels are lower than the control group patients(P<0.05),the incidence of adverse reactions was7.31%,compared with 5.00%in the control group no significant difference(P>0.05).Conclusion 131Ⅰplus the hyperthyroidism drug for the treatment of hyperthyroidism clinical curative effect is superior to the single use of hyperthyroidism drug therapy,and does not increase the incidence of adverse drug reactions patients,with application feasibility.